|
Who's Doing
What
Grants
7/92-6/93 American Heart Association Fellowship Grant
"Familial Hypertrophic Cardiomyopathy: Genetic Linkage Studies $22,000
7/95-6/98 American Heart Association
"Identification of Genetic Modifiers for Familial Hypertrophic
Cardiomyopathy" $70,000
10/95-9/01 NIH "Familial Hypertrophic
Cardiomyopathy: Linkage Studies" "430,920
1997 Penn State University
Clinical Research Center Grant
"Autonomic Function Testing in Pediatric Patients with Symptoms of
Chronic Orthostatic Intolerance" $10,000
9/98-8/99 Children’s Miracle Network
"Hypertrophic Cardiomyopathy" $13,500
7/99-6/01 American Heart Association
"Identification of a New Genetic Locus for a Familial Hypertrophic-Restrictive
Cardiomyopathy Phenotype" $90,000
Cyran SE (Principal Investigator): Cardioplegia,
cytosolic calcium and the developing heart. NIH K08 02510-01. Approved
but not funded, May 1990.
Cyran SE (Principal Investigator): Mechanisms of
alterations in cytosolic free calcium following cardioplegia in the
developing heart. American Heart Association, Western Pennsylvania
Chapter. Funded, 1990. Support for two year period July 1, 1990 - June
30, 1992 ($25,000/year).
Greecher CP (Principal Investigator), Cyran SE, Kaplan
KM, Localio RA: The effect of aerobic and resistance training on
cardiovascular fitness and resting energy expenditure in obese children.
Children's Miracle Network Telethon, Funded, September 1, 1991 - August
31, 1992 ($19,140 total).
Haas J (Principal Investigator), Cyran SE, Tinker DE,
Landis JR, Simon L: Psychological influences on "perceived
exertion" in children. Children's Miracle Network Telethon, Funded,
1992 ($6,200).
Cilley RE (Principal Investigator), Cyran
(Co-Investigator): Rational transfusion therapy: Predicting the need for
red blood cell transfusion by physiologic measurements. Four Diamonds
Pediatric Oncologic Society, June 1993.
Cyran SE (Principal Investigator): Doxorubicin (Adriamycin)
Toxicity in the Developing Heart: Alterations in Myocyte Calcium
Metabolism as a Mechanism for Systolic and Diastolic Dysfunction. Four
Diamonds Pediatric Oncologic Society, Funded May 1993 ($25,000).
A Phase IV Study of the Safety of Palivizumat (MEDI-493,
SynagisÔ ) for the Prophylaxis of
Respiratory Syncytial Virus in Children with Congenital Heart Disease.
Medimmune – Sponsor Protocol XI-CP048. Principal Investigator – HMC
Site. $52,557
|
